TIANDA PHARMA (00455) announced its interim results, with a net loss attributable to shareholders of HKD 32.25 million, narrowing by 2.97% year-on-year.
Tian Da Pharmaceutical (00455) announced its mid-term results for 2026, with revenue of approximately HKD 164 million, a year-on-year increase of 20.19%. The company's loss attributable to shareholders was HKD 32.25 million, a year-on-year narrowing of 2.97%. The loss per share was HKD 0.015.
TIANDA PHARMA (00455) announced its interim results for 2026, with revenue of approximately HKD 164 million, a year-on-year increase of 20.19%; the company's loss attributable to shareholders narrowed to HKD 32.25 million, a decrease of 2.97% year-on-year; loss per share was HKD 0.015.
The announcement stated that during the period, the group continuously optimized its sales strategy, integrated resources, and improved operational efficiency, consolidating the market foundation for its core products, expanding diversified channels, advancing innovation and research and development in traditional Chinese medicine, and building its product pipeline, while enhancing the overall layout of the traditional Chinese medicine industry chain. The group strengthened refined management and cost reduction to increase efficiency, achieving double-digit growth in overall revenue and improving operational quality.
Related Articles
US Stock Market Move | Due to the failure of a competitor's drug development to meet its goals, Vertex Pharmaceuticals Incorporated (VRTX.US) rose nearly 7%.
A-share evening highlights | Important document! The central bank's latest deployment has been released, mentioning financial markets, consumption, and more.
GLOBAL NEW MAT (06616) issues a profit warning, expecting a mid-term loss of approximately 50 million to 100 million yuan, experiencing a year-on-year shift from profit to loss.
US Stock Market Move | Due to the failure of a competitor's drug development to meet its goals, Vertex Pharmaceuticals Incorporated (VRTX.US) rose nearly 7%.
A-share evening highlights | Important document! The central bank's latest deployment has been released, mentioning financial markets, consumption, and more.
GLOBAL NEW MAT (06616) issues a profit warning, expecting a mid-term loss of approximately 50 million to 100 million yuan, experiencing a year-on-year shift from profit to loss.
RECOMMEND
